CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Performance of the CMS muon detector and muon reconstruction with proton-proton collisions at root s=13 TeV

The CMS muon detector system, muon reconstruction software, and high-level trigger underwent significant changes in 2013-2014 in preparation for running at higher LHC collision energy and instantaneous luminosity. The performance of the modified system is studied using proton-proton collision data at center-of-mass energy root s = 13 TeV, collected at the LHC in 2015 and 2016. The measured performance parameters, including spatial resolution, efficiency, and timing, are found to meet all design specifications and are well reproduced by simulation. Despite the more challenging running conditions, the modified muon system is found to perform as well as, and in many aspects better than, previously. We dedicate this paper to the memory of Prof. Alberto Benvenuti, whose work was fundamental for the CMS muon detector.Peer reviewe

On the Lagrangian formulation of the double copy to cubic order

We investigate the Lagrangian formulation of the double-copy correspondence between gauge theories and gravity, up to the cubic order. Building on the definition of the double-copy field as a convolution of two vectors, we obtain free gravitational Lagrangians as products of two Yang-Mills Lagrangians, in a form amenable to be easily extended to the massive case. We discuss the origin of these results from tensionless strings and show the existence of gauge fixings that mix the two spin-one sectors and lead to an alternative, especially simple, version of the free Lagrangian. We then construct cubic vertices for the full double-copy multiplet, comprising a graviton, a two-form and a scalar particle, by means of the Noether procedure. Both at the free and at the cubic level the result gets uniquely fixed only upon imposing, on top of gauge invariance, a left-right Lorentz symmetry ruling contraction of indices among double-copy fields. Whereas the outcome nicely matches the cubic interactions of N = 0 supergravity, including the gauge-invariant coupling between the scalar particle and the two-form, such a twofold Lorentz symmetry seems to conflict with the perturbative reconstruction of spacetime geometry

CMS drift tubes readout phase 1 upgrade

Topical Workshop on Electronics for Particle Physics (2018. Antwerp, Belgium

Kaposiform hemangioendothelioma further broadens the phenotype of PIK3CA-related overgrowth spectrum

Kaposiform hemangioendothelioma (KHE) is a rare locally aggressive mixed vascular tumor, with typical onset in early childhood and characterized by progressive angio- and lymphangiogenesis. Its etiopathogenesis and molecular bases are still unclear. Here, we report the first case of congenital KHE harboring a PIK3CA mosaic pathogenic variant (c.323G > A, p.Arg108His) in a boy with very subtle PIK3CA-related overgrowth spectrum (PROS) features. This finding provides insights into the pathophysiology of KHE, offering targeted therapeutic options by inhibition of the PI3K/Akt/mTOR pathway. We propose the inclusion of this mixed lymphatic and vascular anomaly within the PROS

Phase II study of weekly paclitaxel and sorafenib as second/third line therapy in patients with adrenocortical carcinoma.

BACKGROUND: There is a strong rationale in the use of antiangiogenic therapy in the management of adrenocortical carcinoma (ACC). Metronomic administration of chemotherapy and antiangiogenic drugs can be synergistic in targeting endothelial cells. OBJECTIVE: We assessed the activity of sorafenib plus metronomic paclitaxel as second/third-line therapy in advanced ACC patients. We also tested the activity of sorafenib and paclitaxel against NCI-H295R in vitro. DESIGN: Multicenter, prospective phase II trial. Setting Referral centers for ACC. METHODS: Twenty-five consecutive metastatic ACC patients who progressed after mitotane plus one or two chemotherapy lines were planned to be enrolled. The patients received a combination of i.v. paclitaxel (60 mg/m(2) every week) and oral sorafenib (400 mg twice a day) till progression. The primary aim was to measure the progression-free survival rate after 4 months and the secondary aims were to assess the objective response rate and toxicity. RESULTS: Tumor progression was observed in nine evaluable patients at the first assessment. These results led to the premature interruption of the trial. The treatment was well tolerated. The most relevant toxicities were fatigue, being grade 2 or 3 in four patients, and hypophosphatemia, being grade 3 in three patients. In the in vitro study, sorafenib impaired the viability of H295R cells with dose-response and time-response relationships. The in vitro sorafenib activity was not increased in combination with paclitaxel. CONCLUSIONS: Despite the in vitro activity, sorafenib plus weekly paclitaxel is an inactive salvage treatment in patients with advanced ACC and should not be recommended

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200 mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotane administration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1 patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients (39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed. Treatment was well tolerated, with grade III and IV toxicities consisting of leukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), and mucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73) respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-tolerated and moderately active regimen in heavily pretreated ACC patients

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200 mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotane administration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1 patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients (39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed. Treatment was well tolerated, with grade III and IV toxicities consisting of leukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), and mucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73) respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-tolerated and moderately active regimen in heavily pretreated ACC patients

Study of the effects of radiation on the CMS Drift Tubes Muon Detector for the HL-LHC

The CMS drift tubes (DT) muon detector, built for withstanding the LHC expected integrated and instantaneous luminosities, will be used also in the High Luminosity LHC (HL-LHC) at a 5 times larger instantaneous luminosity and, consequently, much higher levels of radiation, reaching about 10 times the LHC integrated luminosity. Initial irradiation tests of a spare DT chamber at the CERN gamma irradiation facility (GIF++), at large (similar to O(100)) acceleration factor, showed ageing effects resulting in a degradation of the DT cell performance. However, full CMS simulations have shown almost no impact in the muon reconstruction efficiency over the full barrel acceptance and for the full integrated luminosity. A second spare DT chamber was moved inside the GIF++ bunker in October 2017. The chamber was being irradiated at lower acceleration factors, and only 2 out of the 12 layers of the chamber were switched at working voltage when the radioactive source was active, being the other layers in standby. In this way the other non-aged layers are used as reference and as a precise and unbiased telescope of muon tracks for the efficiency computation of the aged layers of the chamber, when set at working voltage for measurements. An integrated dose equivalent to two times the expected integrated luminosity of the HL-LHC run has been absorbed by this second spare DT chamber and the final impact on the muon reconstruction efficiency is under study. Direct inspection of some extracted aged anode wires presented a melted resistive deposition of materials. Investigation on the outgassing of cell materials and of the gas components used at the GIF++ are underway. Strategies to mitigate the ageing effects are also being developed. From the long irradiation measurements of the second spare DT chamber, the effects of radiation in the performance of the DTs expected during the HL-LHC run will be presented